产品名称
Trehalose monooleate, Avanti Research™ - A Croda Brand 890809P, powder
InChI
1S/C30H54O12/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-22(32)39-19-21-24(34)26(36)28(38)30(41-21)42-29-27(37)25(35)23(33)20(18-31)40-29/h9-10,20-21,23-31,33-38H,2-8,11-19H2,1H3/b10-9-/t20-,21-,23-,24-,25+,26+,27-,28-,29-,30-/m1/s1
InChI key
MLVMMWOWJSIKLS-WYVBACLFSA-N
SMILES string
O[C@H]([C@@H](COC(CCCCCCC/C=C\CCCCCCCC)=O)O[C@H](O[C@@H](O[C@@H]([C@H]([C@@H]1O)O)CO)[C@@H]1O)[C@@H]2O)[C@@H]2O
form
powder
packaging
pkg of 1 × 10 mg (890809P-10mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand 890809P
shipped in
dry ice
storage temp.
−20°C
Biochem/physiol Actions
Trehalose monooleate is derived from sugar and fatty acid moieties. It is found to possess anti-aggregation activity. Trehalose monooleate has a sustaining effect against agitation and heat stress in protein. It is considered nonhemolytic and nontoxic. Trehalose monooleate is employed in solid lipid nanoparticles for treating psoriasis.
Packaging
5 mL Amber Glass Screw Cap Vial (890809P-10mg)
Other Notes
For R&D use only. Not for drug, household, or other uses.
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
存储类别
11 - Combustible Solids
wgk
WGK 3
法规信息
涉药品监管产品
此项目有
Nanomaterials for Clinical Applications: Case Studies in Nanomedicines, 17-17 (2020)
Smita S Kale et al.
Molecular pharmaceutics, 13(12), 4082-4093 (2016-10-12)
Protein aggregation is a major problem of therapeutic proteins because aggregation decreases their therapeutic activity and shelf life and induces immunogenicity. Stabilization against aggregation is commonly attained by addition of different excipients like sugars, surfactants, buffers, salts, amino acids, polymers
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持